Recruiting Alzheimers Disease Studies in Savannah
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, follow...
Study to Evaluate NRCT-101SR in Pediatric Subjects with ADHD
To evaluate the efficacy and safety of NRCT-101SR compared to placebo in subjects 13-17 years of age with ADHD...
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
The main objective of this study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the doubl...
A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder
A combination therapy of NRCT-101 with NRCT-202 is being developed for patients with ADHD....
About Alzheimers Disease Clinical Trials in Savannah
Alzheimer's disease is a progressive brain disorder that destroys memory, thinking skills, and the ability to carry out daily tasks. It is the most common cause of dementia, affecting over 6.7 million Americans age 65 and older. The disease is characterized by amyloid-beta plaques and tau tangles in the brain. Recent FDA approvals of anti-amyloid antibodies like lecanemab (Leqembi) and donanemab have opened a new era of disease-modifying treatments. Clinical trials are now exploring next-generation amyloid-clearing therapies, tau-targeting treatments, anti-inflammatory approaches, and combination strategies. Early-stage patients with mild cognitive impairment or early Alzheimer's are frequently sought for enrollment, and many trials now use blood-based biomarkers for screening.
There are currently 4 alzheimers disease clinical trials recruiting participants in Savannah, GEORGIA. These studies are seeking a combined 552 participants. Research is being sponsored by Zura Bio Inc, Neurocentria, Inc., Hoffmann-La Roche. Clinical trial participation is free and participants receive study-related medical care at no cost.
Alzheimers Disease Clinical Trials in Savannah — FAQ
Are there alzheimers disease clinical trials in Savannah?
Yes, there are 4 alzheimers disease clinical trials currently recruiting in Savannah, GEORGIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Savannah?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Savannah research site will contact you about next steps.
Are clinical trials in Savannah free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Savannah studies also compensate for your time and travel.
What alzheimers disease treatments are being tested?
The 4 active trials in Savannah are testing new therapies including novel drugs, biologics, and treatment approaches for alzheimers disease.
Data updated March 2, 2026 from ClinicalTrials.gov